gabapentin has been researched along with Body Weight in 10 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors reviewed changes in body weight in 44 patients treated with Gabapentin (GPN) for a period of 12 or more months." | 7.69 | Changes in body weight with chronic, high-dose gabapentin therapy. ( DeCerce, J; DeToledo, JC; Ramsay, RE; Toledo, C, 1997) |
| "Gabapentin was administered in single doses of 10 mg/kg (N=48 healthy subjects, age 1 month-12 years) or in multiple doses of 10-65 mg/kg per day (N=205 patients with epilepsy, age 2 months-13 years) at 08:00, 14:00, and 20:00." | 5.09 | Population pharmacokinetics of gabapentin in infants and children. ( Bockbrader, HN; Garofalo, E; Ouellet, D; Shapiro, DY; Wesche, DL, 2001) |
| "A total of 60 pregnant mice, divided into 12 groups of five mice each, were exposed to gabapentin in four different doses of 0 (control), 113, 226, or 452 mg/kg body weight per day, at three different gestational stages including early gestation (1-6 days), mid-gestation (7-12 days), and late gestation (13-17 days)." | 3.74 | Teratogenic effects of the anticonvulsant gabapentin in mice. ( Goel, RK; Madhyastha, S; Nasar, MA; Pai, MM; Prabhu, LV; Rai, R; Singh, G; Yadav, SK, 2008) |
| "several parameters, concerning fertility were measured in 40 albino male rats of Sprague Dawley strain, they were divided into 4 groups, group one received vehicle (distilled water), group two received Vigabatrin in a dose of 200 mg/kg body weight, group three received Lamotrigine in a dose of 30 mg/kg body weight, and group four received Gabapentin 100 mg/kg body weight." | 3.72 | The effect of Vigabatrin, Lamotrigine and Gabapentin on the fertility, weights, sex hormones and biochemical profiles of male rats. ( Abdul-Zahra, E; Bataineh, H; Daoud, AS; Otoom, S, 2004) |
| "The authors reviewed changes in body weight in 44 patients treated with Gabapentin (GPN) for a period of 12 or more months." | 3.69 | Changes in body weight with chronic, high-dose gabapentin therapy. ( DeCerce, J; DeToledo, JC; Ramsay, RE; Toledo, C, 1997) |
| "Koumine treatment of diabetic rats decreased neuropathic pain behavior as early as after the first administration." | 1.40 | Anti-allodynic and neuroprotective effects of koumine, a Benth alkaloid, in a rat model of diabetic neuropathy. ( Huang, HH; Ling, Q; Liu, M; Wu, MX; Xu, Y; Yang, J; Yu, CX, 2014) |
| "Reproductive endocrine disturbances are a major health concern in women with epilepsy due to their long term use of antiepileptic drugs (AEDs)." | 1.40 | Second generation anti-epileptic drugs adversely affect reproductive functions in young non-epileptic female rats. ( Kaur, G; Kumar, S, 2014) |
| "Huntington's disease is a progressive neurodegenerative disorder that gradually reduces memory, cognitive skills and normal movements of affected individuals." | 1.38 | Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity. ( Kalonia, H; Kumar, A; Kumar, P, 2012) |
| "Gabapentin displays efficacy against abnormal sensory processing in diabetic rats and may be of benefit for treating painful diabetic neuropathy." | 1.30 | Gabapentin prevents hyperalgesia during the formalin test in diabetic rats. ( Calcutt, NA; Ceseña, RM, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ling, Q | 1 |
| Liu, M | 1 |
| Wu, MX | 1 |
| Xu, Y | 1 |
| Yang, J | 1 |
| Huang, HH | 1 |
| Yu, CX | 1 |
| Kumar, S | 1 |
| Kaur, G | 1 |
| Kumar, P | 1 |
| Kalonia, H | 1 |
| Kumar, A | 1 |
| Daoud, AS | 1 |
| Bataineh, H | 1 |
| Otoom, S | 1 |
| Abdul-Zahra, E | 1 |
| Pandey, CK | 1 |
| Navkar, DV | 1 |
| Giri, PJ | 1 |
| Raza, M | 1 |
| Behari, S | 1 |
| Singh, RB | 1 |
| Singh, U | 1 |
| Singh, PK | 1 |
| Prabhu, LV | 1 |
| Rai, R | 1 |
| Pai, MM | 1 |
| Yadav, SK | 1 |
| Madhyastha, S | 1 |
| Goel, RK | 1 |
| Singh, G | 1 |
| Nasar, MA | 1 |
| DeToledo, JC | 1 |
| Toledo, C | 1 |
| DeCerce, J | 1 |
| Ramsay, RE | 1 |
| Ceseña, RM | 1 |
| Calcutt, NA | 1 |
| Nozaki-Taguchi, N | 1 |
| Chaplan, SR | 1 |
| Higuera, ES | 1 |
| Ajakwe, RC | 1 |
| Yaksh, TL | 1 |
| Ouellet, D | 1 |
| Bockbrader, HN | 1 |
| Wesche, DL | 1 |
| Shapiro, DY | 1 |
| Garofalo, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187] | 8 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to PI left institution) | |||
| Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903] | Phase 4 | 77 participants (Actual) | Interventional | 2018-05-15 | Completed | ||
| Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures[NCT02957097] | Phase 4 | 0 participants (Actual) | Interventional | 2019-09-30 | Withdrawn (stopped due to Original PI left institution and the PI who took over was not able to initiate the study so it was never started.) | ||
| The Effect of Gabapentin on Acute Pain and PONV in Bariatric Surgical Patients[NCT00886236] | 62 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)
| Intervention | score on 10-point scale (Mean) |
|---|---|
| Standard of Care | 2.26 |
| Postoperative Gabapentin Regimen | 2.46 |
Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 3.84 |
| Postoperative Gabapentin Regimen | 3.54 |
Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 5.73 |
| Postoperative Gabapentin Regimen | 6.38 |
Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 0.36 |
| Postoperative Gabapentin Regimen | 0.17 |
Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 7.83 |
| Postoperative Gabapentin Regimen | 8.48 |
Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | days (Mean) |
|---|---|
| Standard of Care | 14.8 |
| Postoperative Gabapentin Regimen | 18.7 |
Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).
| Intervention | morphine equivalents (Mean) |
|---|---|
| Standard of Care | 287.0 |
| Postoperative Gabapentin Regimen | 281.1 |
(NCT00886236)
Timeframe: 48 hours
| Intervention | % oxygen saturation (Mean) |
|---|---|
| 1 Preoperative Gabapentin Liquid | 93 |
| 2 Preoperative and Postoperative Gabapentin Liquid | 94 |
| 3 Preoperative and Postoperative Placebo Liquid | 95 |
The amount of intraoperative and postoperative opioids used will be collected and analyzed for the three different arms. (NCT00886236)
Timeframe: 120 hours
| Intervention | ml (Mean) |
|---|---|
| 1 Preoperative Gabapentin Liquid | 11.035 |
| 2 Preoperative and Postoperative Gabapentin Liquid | 8.7 |
| 3 Preoperative and Postoperative Placebo Liquid | 12.4 |
(NCT00886236)
Timeframe: 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Preoperative Gabapentin Liquid | 12 |
| 2 Preoperative and Postoperative Gabapentin Liquid | 11 |
| 3 Preoperative and Postoperative Placebo Liquid | 12 |
2 trials available for gabapentin and Body Weight
| Article | Year |
|---|---|
Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Body Weight; Cyclohexa | 2005 |
Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Body Weight; Cyclohexa | 2005 |
Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Body Weight; Cyclohexa | 2005 |
Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Body Weight; Cyclohexa | 2005 |
Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Body Weight; Cyclohexa | 2005 |
Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Body Weight; Cyclohexa | 2005 |
Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Body Weight; Cyclohexa | 2005 |
Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Body Weight; Cyclohexa | 2005 |
Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Body Weight; Cyclohexa | 2005 |
Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Body Weight; Cyclohexa | 2005 |
Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Body Weight; Cyclohexa | 2005 |
Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Body Weight; Cyclohexa | 2005 |
Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Body Weight; Cyclohexa | 2005 |
Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Body Weight; Cyclohexa | 2005 |
Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Body Weight; Cyclohexa | 2005 |
Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Body Weight; Cyclohexa | 2005 |
Population pharmacokinetics of gabapentin in infants and children.
Topics: Acetates; Adolescent; Amines; Anticonvulsants; Body Weight; Child; Child, Preschool; Creatinine; Cyc | 2001 |
8 other studies available for gabapentin and Body Weight
| Article | Year |
|---|---|
Anti-allodynic and neuroprotective effects of koumine, a Benth alkaloid, in a rat model of diabetic neuropathy.
Topics: Amines; Animals; Blood Glucose; Body Weight; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experim | 2014 |
Second generation anti-epileptic drugs adversely affect reproductive functions in young non-epileptic female rats.
Topics: Amines; Animals; Anticonvulsants; Astrocytes; Blotting, Western; Body Weight; Cyclohexanecarboxylic | 2014 |
Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity.
Topics: Amines; Animals; Body Weight; Brain; Catalase; Cyclohexanecarboxylic Acids; GABAergic Neurons; Gabap | 2012 |
The effect of Vigabatrin, Lamotrigine and Gabapentin on the fertility, weights, sex hormones and biochemical profiles of male rats.
Topics: Amines; Analgesics; Animals; Antimanic Agents; Body Weight; Cyclohexanecarboxylic Acids; Female; Fer | 2004 |
Teratogenic effects of the anticonvulsant gabapentin in mice.
Topics: Abnormalities, Drug-Induced; Amines; Animals; Anticonvulsants; Body Weight; Congenital Abnormalities | 2008 |
Changes in body weight with chronic, high-dose gabapentin therapy.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Body Weight; Cyclohexanecarboxylic Acids; Fema | 1997 |
Gabapentin prevents hyperalgesia during the formalin test in diabetic rats.
Topics: Acetates; Amines; Analgesics; Animals; Blood Glucose; Body Weight; Cyclohexanecarboxylic Acids; Diab | 1999 |
Vincristine-induced allodynia in the rat.
Topics: Acetates; Amines; Analgesics; Animals; Antineoplastic Agents, Phytogenic; Body Weight; Cyclohexaneca | 2001 |